Eficacia de la terapia con aminoglicósidos en infectados por Klelsiella pneumoniae resistente a carbapenémicos
DOI:
https://doi.org/10.37135/ee.04.15.10Palabras clave:
aminoglicósidos, Klebsiella pneumoniae, Enterobacteriaceae resistentes a los carbapenémicosResumen
El tratamiento de infecciones por bacterias resistentes a determinados grupos farmacológicos resulta un tema de alto interés para la ciencia. Así, la investigación tuvo el propósito de sistematizar la información acerca de la eficacia de los aminoglicósidos en pacientes infectados por Klebsiella pneumoniae resiste a carbapenémicos; para lo que se hizo una revisión sistemática siguiendo el protocolo PRISMA. Las fuentes se ubicaron a partir de una pesquisa se hizo en las bases de datos: PubMed, MEDLINE y SCOPUS; quedando seleccionados 11 artículos que cumplieron con los requisitos establecidos. Se observó un predominio de los artículos provenientes de los Estados Unidos de América (4/11) y Brasil (3/11). La población global fue de 3778 pacientes entre las 11 investigaciones incluidas. El uso de aminoglicósidos resultó más eficaz que otros grupos farmacológicos en la mejoría en el estado clínico, reflejando menores valores de mortalidad en pacientes hospitalizados por la infección en cuestión.
Descargas
Citas
Almaghrabi R, Clancy C, Doi Y, Hao B, Chen L, Shields R. Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. Antimicrobial Agents and Chemotherapy [Internet]. 2014 [citado 21 Sep 2021]; 58(8): 4443. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135979/.
Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrobial agents and chemotherapy [Internet]. 2011 [citado 21 Sep 2021]; 55(4): 1485-1493. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21282452/.
Rice LV, Carias LL, Hutton RA, Rudin SD, Endimiani A, Bonomo RA. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrobial agents and chemotherapy [Internet]. 2008 [citado 21 Sep 2021]; 52(9): 3427-3429. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18573935/.
Gutiérrez-Gutiérrez B, Salamanca E, Cueto M, Hsueh P, Viale P, Paño-Pardo J, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. The Lancet Infectious Diseases [Internet]. 2017 [citado 21 Sep 2021]; 17(7): 726-734. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1473309917302281.
Clancy CJ, Hao B, Shields RK, Chen L, Perlin DS, Kreiswirth BN, et al. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrobial agents and chemotherapy [Internet]. 2014 [citado 21 Sep 2021]; 58(6): 3521-3525. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24566172/.
Kishk R, Soliman N, Nemr N, Eldesouki R, Mahrous N, Gobouri A, et al. Prevalence of aminoglycoside resistance and aminoglycoside modifying enzymes in acinetobacter Baumannii among intensive care unit patients, Ismailia, Egypt. Infect Drug Resist [Internet]. 2021[citado 21 Sep 2021]; 14: 143-150. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33519215/.
Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. Drug Resist Updat [Intenet]. 2010 [citado 21 Sep 2021]; 13(6): 151-171. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20833577/.
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrobial agents and chemotherapy [Internet]. 2011 [citado 30 Sep 2021]; 55(12): 5893-5899. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21968368/.
Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. The Journal of antimicrobial chemotherapy [Internet]. 2015 [citado 25 Sep 2021]; 70(3): 905-913. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25344809/.
Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, AggenJB, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrobial agents and chemotherapy [Internet]. 2009 [citado 23 Sep 2021]; 53(10): 4504-4507. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19770287/.
Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. The Journal of antimicrobial chemotherapy [Internet]. 2011 [citado 21 Sep 2021]; 66(1): 48-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21078604/.
Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. Journal of chemotherapy [Internet]. 2012 [citado 16 Sep 2021]; 24(4): 191-194. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23040681/.
Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest [Internet]. 2005 [citado 11 Sep 2021]; 128(2): 545-552. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16100136/.
Pitt HA, Roberts RB, Johnson WD. Gentamicin levels in the human biliary tract. The Journal of infectious diseases [Internet]. 1973 [citado 13 Sep 2021]; 127(3): 299-302. Disponible en: https://pubmed.ncbi.nlm.nih.gov/4688926/.
Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin [Internet]. 2010 [citado 21 Sep 2021]; 135(11): 507-511. Disponible en: https://es.cochrane.org/sites/es.cochrane.org/files/public/uploads/PRISMA_Spanish.pdf.
National Heart, Lung, and Blood Institute. Herramienta de evaluación de la calidad para estudios observacionales de cohortes y transversales [Internet]. Bethesda: NHLBI; 2013 [actualizado Jul 2021; citado el 19 de setiembre de 2021]. Disponible en: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
Rodrigues D, Baldissera G, Mathos D, Sartori A, Zavascki A, Rigatto M. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. Brazilian Journal of Microbiology [Internet]. 2021 [citado 27 Dic 2021]; 52(4):1913-1919. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34191252/.
Bellomo R, Ronco C, Kellum JA, Metha RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care [Internet]. 2004 [citado 21 Sep 2021]; 8(4): 204-212. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15312219/.
Freire MP, de Oliveira Garcia D, Cury AP, Francisco GR, Dos Santos NF, Spadão F, et al. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology [Internet]. 2019 [citado 21 Sep 2021]; 38(4): 755-765. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30680569/.
Rodrigues Dos Santos BG, Amaral ES, Fernandes PF, Oliveira CM, Rodrigues JL, Perdigão Neto LV, et al. Urinary Tract Infections and Surgical Site Infections due to Carbapenem-Resistant Enterobacteriaceae in Renal Transplant. Transplantation proceedings [Internet]. 2016 [citado 21 Sep 2021]; 48(6): 2050-2055. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27569943/.
McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, et al. Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. The New England journal of medicine [Internet]. 2019 [citado 21 Sep 2021]; 380(8): 791-793. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30786196/.
Wagenlehner F, Cloutier D, Komirenko A, Cebrik D, Krause K, Keepers T, et al. Once-daily plazomicin for complicated urinary tract infections. Journal of Urology [Internet]. 2019 [citado 21 Sep 2021]; 202(4): 641-642. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1801467.
Connolly L, Riddle V, Cebrik D, Armstrong E, Miller L. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrobial Agents and Chemotherapy [Internet]. 2018 [citado 12 Sep 2021]; 62(4): 1989-2017. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913993/.
Lee Y, Hsiao C, Hung M, Hung S, Wang H, Huang Y, et al. Bacteremic Urinary Tract Infection Caused by Multidrug-Resistant Enterobacteriaceae Are Associated with Severe Sepsis at Admission. Medicine (United States) [Internet]. 2016 [citado 19 Sep 2021]; 95(20): e3694. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902422/.
Shields R, Clancy C, Press E, Nguyen M. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy [Internet]. 2016 [citado 4 Oct 2021]; 60(5): 3187-3192. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862490/.
Connolly LE, Jubb A, O’Keeffe B, Serio AW, Smith A, Gall J, et al. Plazomicin is associated with improved survival and safety compared with colistin in the treatment of serious infections due to carbapenem-resistant Enterobacteriaceae: results of the CARE Study. New Orleans: 2nd American Society for Microbiology Microbe; 2017.
Zohar I, Schwartz O, Yossepowitch O, David S, Maor Y. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy [Internet]. 2020 [citado 29 Sep 2021]; 75(2): 458-465. Disponible en: https://academic.oup.com/jac/article/75/2/458/5613763.
Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. Journal of Antimicrobial Chemotherapy [Internet]. 2020 [citado 27 Sep 2021]; 75(8): 2307-2313. Disponible en: https://academic.oup.com/jac/article/75/8/2307/5843906.
